Home Cart 0 Sign in  

[ CAS No. 1448671-31-5 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 1448671-31-5
Chemical Structure| 1448671-31-5
Structure of 1448671-31-5 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 1448671-31-5 ]

Related Doc. of [ 1448671-31-5 ]

Alternatived Products of [ 1448671-31-5 ]

Product Details of [ 1448671-31-5 ]

CAS No. :1448671-31-5 MDL No. :MFCD28963899
Formula : C21H24F3N5O5S Boiling Point : -
Linear Structure Formula :- InChI Key :PRNXOFBDXNTIFG-FQEVSTJZSA-N
M.W : 515.51 Pubchem ID :10369242
Synonyms :

Calculated chemistry of [ 1448671-31-5 ]

Physicochemical Properties

Num. heavy atoms : 35
Num. arom. heavy atoms : 14
Fraction Csp3 : 0.52
Num. rotatable bonds : 6
Num. H-bond acceptors : 9.0
Num. H-bond donors : 2.0
Molar Refractivity : 125.65
TPSA : 150.69 Ų

Pharmacokinetics

GI absorption : Low
BBB permeant : No
P-gp substrate : Yes
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : Yes
Log Kp (skin permeation) : -8.0 cm/s

Lipophilicity

Log Po/w (iLOGP) : 3.14
Log Po/w (XLOGP3) : 2.04
Log Po/w (WLOGP) : 2.89
Log Po/w (MLOGP) : 2.3
Log Po/w (SILICOS-IT) : 4.04
Consensus Log Po/w : 2.88

Druglikeness

Lipinski : 1.0
Ghose : None
Veber : 1.0
Egan : 1.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -4.22
Solubility : 0.031 mg/ml ; 0.0000601 mol/l
Class : Moderately soluble
Log S (Ali) : -4.83
Solubility : 0.00758 mg/ml ; 0.0000147 mol/l
Class : Moderately soluble
Log S (SILICOS-IT) : -4.47
Solubility : 0.0176 mg/ml ; 0.0000342 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 4.72

Safety of [ 1448671-31-5 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 1448671-31-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 1448671-31-5 ]

[ 1448671-31-5 ] Synthesis Path-Downstream   1~2

  • 1
  • [ 1448671-31-5 ]
  • [ 4595-60-2 ]
  • [ 733810-35-0 ]
YieldReaction ConditionsOperation in experiment
With copper(l) iodide; trans-1,2-Diaminocyclohexane; potassium carbonate In 1,4-dioxane at 100℃; for 16h; 26 (45)-4-METHYL-2-[L 1, 2,3, 4-TETRAHYDRO-3-METHYL-1- (L-METHYLETHYL)-6-FF5-METHYL-L- (2- PYRIMIDINML)-3- (TRIFLUOROMETHYL)-L1-PYRAZOL-4-YLLXMETHYLL-2, 4-DIOXOTHIENOF2, 3- d]pyrimidin-5-yl]carbonyl]- 4-isoxazolidinol A mixture of the product of example 10 part b) (279mg), 2-bromopyrimidine (300mg), copper (I) iodide (95mg), TRANS-CYCLOHEXANEDIAMINE (55mg) and potassium carbonate (300MG) in dioxane (2ml) was heated at 100C for 16hours under nitrogen. The reaction mixture was concentrated to dryness and purified by silica chromatography eluting with an ethyl acetate to 10% methanol/ ethyl acetate gradient, followed by RPHPLC to give the title compound as a white solid (105MG). MS (APCI+ve) 494 [M+H] + 8'HDMSO, 120C 1.40 (3H, s), 1.47 (6H, d), 2.53 (3H, s), 3.21 (3H, s), 3.64-3. 72 (3H, m), 3.80 (1H, d), 4.07 (2H, s), 4.46 (sep, 1H), 7.59 (1H, t), 8.94 (2H, d)
  • 2
  • [ 644970-79-6 ]
  • [ 733810-92-9 ]
  • [ 1448671-31-5 ]
YieldReaction ConditionsOperation in experiment
Stage #1: 1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-6-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-2,4-dioxo-thieno[2,3-d]pyrimidine-5-carboxylic acid With benzotriazol-1-ol; diethyl chlorophosphate; triethylamine In DMF (N,N-dimethyl-formamide) at 20℃; for 1.25h; Stage #2: (4S)-4-methylisoxazolidin-4-ol hydrochloric salt In DMF (N,N-dimethyl-formamide) at 20℃; for 20h; 10.b 5- (45)-4-HYDROXY-4-METHYL-2-ISOXAZOLIDINYL] CARBONYL]-3-METHYL-L-(L-METHYLETHYL) 6-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-thieno[2,3-d]pyrimidine- 2, 4 (1H, 3H)-DIONE To a suspension of the product of part a) (0.2 g) in anhydrous DIMETHYLFONNAMIDE (3ML), was added triethylamine (0.29 ml), 1-hydroxybenzotriazole (0. 078 g) followed by diethyl chlorophosphate (0.075 ml) and the mixture stirred at ambient temperature under nitrogen for lhr. 15MIN. (4S)-4-Methyl-4-isoxazolidinol hydrochloride (0.07g) was added and the reaction mixture was stirred at ambient temperature for 20hr. It was concentrated under reduced pressure, diluted with saturated sodium bicarbonate solution and extracted with dichloromethane. The organic extracts were dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residue was purified by column chromatography over silica, eluting with dichloromethane/methanol (98 : 2) followed by dichloromethane/methanol (96: 4) to give the title compound as a solid (0. 11 G). MS (ESI) 516 [M+H] + 1HDMSO 1.24-1. 38 (3H, M) ; 1. 44 (6H, s), 2.20 (3H, s), 3.18 (3H, s), 3.62 (2H, m), 3.75 (2H, m), 3. 82 (2H, m), 4.37 (1H, bs), 5.23-5. 42 (1H, m), 13. 38 (1H, bs)
Same Skeleton Products
Historical Records